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Abstract
Background: The increased sympathetic nervous activity in patients with obstructive sleep apnea (OSA) is largely
responsible for the high prevalence of arterial hypertension, and it is suggested to adversely affect triglyceride and high-
density lipoprotein (HDL) cholesterol levels in these patients. The functionally relevant polymorphisms of the β2-
adrenergic receptor (Arg-47Cys/Arg16Gly and Gln27Glu) have been shown to exert modifying effects on these risk
factors in previous studies, but results are inconsistent.
Methods: We investigated a group of 429 patients (55 ± 10.7 years; 361 men, 68 women) with moderate to severe
obstructive sleep apnea (apnea/hypopnea index (AHI) 29.1 ± 23.1/h) and, on average, a high cardiovascular risk profile
(body mass index 31.1 ± 5.6, with hypertension in 60.1%, dyslipidemia in 49.2%, and diabetes in 17.2% of patients). We
typed the β2-adrenergic receptor polymorphisms and investigated the five most frequent haplotypes for their modifying
effects on OSA-induced changes in blood pressure, heart rate, and lipid levels. The prevalence of cardiovascular risk
factors and coronary heart disease (n = 55, 12.8%) and survived myocardial infarction (n = 27, 6.3%) were compared
between the genotypes and haplotypes.
Results: Multivariate linear/logistic regressions revealed a significant and independent (from BMI, age, sex, presence of
diabetes, use of antidiabetic, lipid-lowering, and antihypertensive medication) influence of AHI on daytime systolic and
diastolic blood pressure, heart rate, prevalence of hypertension, and triglyceride and HDL levels. The β2-adrenergic
receptor genotypes and haplotypes showed no modifying effects on these relationships or on the prevalence of
dyslipidemia, diabetes, and coronary heart disease, yet, for all three polymorphisms, heterozygous carriers had a
significantly lower relative risk for myocardial infarction (Arg-47Cys: n = 195, odds ratio (OR) = 0.32, P = 0.012;
Arg16Gly: n = 197, OR = 0.39, P = 0.031; Gln27Glu: OR = 0.37, P = 0.023). Carriers of the most frequent haplotype (n
= 113) (haplotype 1; heterozygous for all three polymorphisms) showed a five-fold lower prevalence of survived
myocardial infarction (OR = 0.21, P = 0.023).
Conclusion: Our study showed no significant modifying effect of the functionally relevant β2-adrenergic receptor
polymorphisms on OSA-induced blood pressure, heart rate, or lipid changes. Nevertheless, heterozygosity of these
polymorphisms is associated with a lower prevalence of survived myocardial infarction in this group with, on average, a
high cardiovascular risk profile.
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Background
Patients with obstructive sleep apnea (OSA) show
increased sympathetic nervous activity during both night
and day [1-3]. This increased sympathetic activity may
contribute to arterial hypertension, increased heart rate
[4,5], and dyslipidemia [6,7]. In addition to exacerbation
of these cardiovascular risk factors, the elevated sympa-
thetic activity makes patients with OSA vulnerable to both
fatal and non-fatal coronary events [8-10]. Sympathetic
activity is mediated by β2-adrenergic receptors, among
others. The receptors are expressed in a wide variety of tis-
sues, including the vascular and bronchial smooth mus-
cles, the heart, and adipocytes. Thus, β2-adrenergic
receptors play a critical role in the regulation of blood
pressure (BP), heart rate, and lipid metabolism. Several
polymorphisms of the β2-adrenergic receptor gene have
been identified. For three polymorphisms, which are the
subject of the present study, functional consequences
have been described [11]:
1) At position -47 in the untranslated region of the β2-
adrenergic receptor gene, a cytosine (C)/thymine (T) pol-
ymorphism results in either arginine (Arg) or cystine
(Cys) in the 5' leader sequence. This sequence encodes a
peptide that modifies β2-adrenergic receptor gene transla-
tion. In human airway smooth muscles, the Cys variant
showed a consistently greater expression of the β2-adren-
ergic receptor [12,13].
2) At position 46 of the coding region, adenine (A) or gua-
nine (G) can be found, resulting in arginine (Arg) or gly-
cine (Gly) at amino acid position 16.
3) At nucleotide position 79, a C/G polymorphism results
in glutamate (Glu) or glutamine (Gln) at amino acid posi-
tion 27.
The latter two polymorphisms and their haplotypes mod-
ify the down-regulation of the β2-adrenergic receptor
upon agonist stimulation. In a previous study [14], the
Gly16/Gln27 haplotype underwent enhanced down-regu-
lation compared with the Arg16/Gln27 haplotype, while
the Arg16/Glu27 haplotype showed almost no down-reg-
ulation. Many population-based studies have been per-
formed to investigate the modifying potency of these
polymorphisms on cardiovascular risk factors in vivo, but
the results have been inconsistent or contradictory.
Previously, a significant negative influence of the severity
of OSA on BP, prevalence of arterial hypertension, heart
rate, and serum levels of high-density lipoprotein choles-
terol (HDL-C) was shown in the parent study cohort of
the patients [4,7] included in this report. In the present
study, we scrutinised the modifying effects of β2-adrener-
gic receptor polymorphisms on these risk factors, which
are mediated by elevated sympathetic activity. We further
investigated whether the three polymorphisms have an
effect on the comparatively high prevalence of coronary
heart disease (CHD) and survived myocardial infarction
(MI) in our patients with OSA.
Methods
Patients and parent study data
The study protocol was approved by the local ethics com-
mittee (Ruhr-University Bochum, Germany). Patients
were consecutively enrolled during the years 1999 to 2001
in the sleep laboratory of the Marienhospital, Herne,
Ruhr-University Bochum, Germany. The patients were
admitted to the hospital because of a history of apnea,
snoring, or hypersomnic symptoms such as daytime tired-
ness or impairment of cognitive functions.
Detailed information on the determination of cardiac risk
factors and polysomnography have been described exten-
sively in previous publications [4,7]. In brief, after
informed consent, the severity of OSA was assessed using
the apnea/hypopnea index (AHI). Dyslipidemia was diag-
nosed by the presence of anamnesis and use of lipid-low-
ering drugs or presence of dyslipidemic serum levels. For
blood analysis, the following cut-off values were defined
as abnormal: total cholesterol ≥ 200 mg/dL, triglycerides
≥ 180 mg/dL, HDL-C ≤ 40 mg/dL, and low-density lipo-
protein cholesterol (LDL-C) ≥ 150 mg/dL. Diabetes was
defined by presence of anamnesis and use of antidiabetic
medication or insulin treatment. The diagnosis of hyper-
tension was established by use of antihypertensive medi-
cation or if the mean of three measured BP readings
exceeded 140 mmHg (systolic) or 90 mmHg (diastolic).
Genotyping
Peripheral blood samples from the patients were taken
after they had given informed consent.
The following primers were synthesised to amplify a 283-
bp fragment containing the Cys-47Arg polymorphism: 5'-
AATGAGGCTTCCAGGCGTC-3' (sense) and 5'-ACTT-
GGCAATGGCTGTGATG-3' (antisense). PCR was carried
out in a final volume of 10 μL with 50 ng DNA, 2 mM
dNTPs and 1 U Taq polymerase. PCR cycling started with
initial denaturation for 5 minutes at 94°C. The annealing
temperature of the first cycle was 69°C, second cycle 66°C
and the remaining 28 cycles 63°C, each cycle being 1
minute. Extension was performed at 72°C for 1 minute
(final extension 5 minutes). Allele-specific restriction
digests were performed with MspAII, which fails to digest
the Cys-47 allele because of the C→G transition. Digested
DNA was separated by electrophoresis on 1.5% agarose
gels.BMC Medicine 2007, 5:1 http://www.biomedcentral.com/1741-7015/5/1
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For the Gly16Arg polymorphism, the following primers
were synthesised to obtain a 96-bp fragment: 5'-GCCAGT-
GCGCTTACCTGC-3' (sense) and 5'-TGGTCCGGCGCAT-
GGCTT-3' (antisense). Final volume of the PCR was 10
μL, containing 50 ng DNA, 2 mM dNTPs, 1 U Taq
polymerase and 1% radioactively labelled dATP. The PCR
cycles after denaturation (94°C for 5 minutes) were 70°C
(1 cycle), 67°C (1 cycle) and 64°C (28 cycles), with each
cycle lasting 1 minute. Extension at 72°C was performed
for 1 minute, and 5 minutes at the end. The PCR products
were digested with the restriction endonuclease NcoI in
order to optimize the demonstration of the polymor-
phism by single-strand conformational polymorphism
analysis. Restriction products were separated in an 8%
polyacrylamide (19:1 acrylamide:bisacrylamide) gel con-
taining 10% glycerol.
For genotyping the Gln27Glu polymorphism, the primers
5'-AAGCCATGCGCCGGACCA-3' (sense) and 5'-ACTT-
GGCAATGGCTGTGATG-3' (antisense) primers were cho-
sen, which produce a 134-bp long product. PCR was
performed with a final volume of 10 μL comprising 50 ng
DNA, 2 mM dNTP and 1 U Taq polymerase. The chosen
temperatures after denaturation were 70.5°C (1 cycle),
67.5°C (1 cycle), and 64.5°C (28 cycles). Allele-specific
restriction was performed with BbvI and bands separated
in a 1.5% agarose gel.
Statistical analysis
Results are presented as means +/-SD. All reported P-val-
ues are two-tailed. Statistical analyses were performed
with SPSS for Windows software (SPSS, Chicago, IL, USA).
Multivariate linear regressions were calculated in order to
determine independent associations between the AHI and
BP, heart rate and lipid serum levels in the presence of
body mass index (BMI), age, and sex. The relationship
between the severity of OSA represented by the AHI and
the prevalence of arterial hypertension was calculated
using multiple logistic regression analysis using BMI, age,
and sex as covariates. Demographic characteristics of the
patients with OSA were compared between the different
genotypes using the χ2 test; P < 0.05 was considered signif-
icant. The phenotypic values were compared between the
genotypes using analysis of variance (ANOVA). Student's
t-test for unpaired samples was used for comparisons
between particular genotypes/haplotypes and the rest of
the group.
An additional model was established in which the
homozygous states of each polymorphism were pooled in
one group and compared with the heterozygous geno-
type. The influence of heterozygosity of each polymor-
phism on survived MI was then analysed in a multivariate
logistic regression model, adjusted for diabetes, dyslipi-
demia, hypertension, sex, BMI, AHI, and age.
Results
The prevalences of the three genotypes are shown in Table
1, which also summarises the demographic findings in the
full study group (n = 429), separated for the different gen-
otypes of the β2-adrenergic receptor polymorphisms.
Allele frequencies of the different polymorphisms were:
Arg-47Cys = 0.53/0.47, Arg16Gly = 0.37/0.63 and
Gln27Glu = 0.49/0.51. The β2-adrenergic receptor poly-
morphisms Arg-47Cys and Gln27Glu were found to be








n (% of n*)
Diabetes
n (% of n*)
Dyslipidemia
n (% of n*)
CHD
n (% of n*)
MI
n (% of n*)
All 429 55.2 ± 10.7 31.1 ± 5.6 258 (60.1) 74 (17.2) 211 (49.2) 55 (12.8) 27 (6.3)
Codon -47
Cys/Cys 131 (24.0) 55.9 ± 11.3 30.8 ± 5.2 76 (58.0) 23 (17.6) 65 (49.6) 16 (12.2) 11 (8.4)
Cys/Arg 195 (45.2) 55.1 ± 10.7 31.1 ± 6.0 119 (61.0) 36 (18.5) 91 (46.7) 25 (12.8) 6 (3.1)
Arg/Arg 103 (30.5) 54.2 ± 9.7 31.5 ± 5.6 63 (61.2) 15 (14.6) 55 (53.4) 14 (13.6) 10 (9.7)
P 0.512 0.705 0.837 0.694 0.539 0.952 0.040
Codon 16
Arg/Arg 59 (13.8) 57.0 ± 9.9 31.6 ± 6.0 34 (57.6) 12 (20.8) 30 (50.8) 6 (10.9) 6 (10.2)
Arg/Gly 197 (45.9) 54.0 ± 11.1 31.1 ± 6.0 121 (61.4) 35 (17.8) 95 (48.2) 23 (11.7) 7 (3.6)
Gly/Gly 173 (40.3) 54.7 ± 10.5 31.0 ± 5.0 103 (59.5) 27 (15.6) 86 (49.7) 26 (15.0) 14 (8.1)
P 0.347 0.790 0.854 0.684 0.924 0.507 0.084
Codon 27
Gln/Gln 109 (25.4) 55.9 ± 11.0 31.5 ± 5.4 67 (61.5) 23 (21.1) 60 (55.0) 16 (14.7) 13 (11.9)
Gln/Glu 202 (47.1) 56.0 ± 10.5 31.0 ± 6.0 117 (57.9) 33 (16.3) 88 (43.6) 24 (11.9) 7 (3.5)
Glu/Glu 118 (27.5) 52.9 ± 10.5 30-9 ± 5.2 74 (62.7) 18 (15.3) 63 (53.4) 15 (12.7) 7 (5.9)
P 0.031 0.746 0.663 0.454 0.087 0.391 0.013
Demographics of the study group (n = 429) and its subgroups with the different genotypes of the β2-adrenergic receptor polymorphisms.
Statistical tests that revealed P-values below 0.1 are in bold. There were significantly lower rates for MI in heterozygous genotypes of Cys-47Arg 
and the Gln27Glu polymorphisms in spite of the significant older age in the Gln27Glu variant. In addition, there wass also a trend for a lower rate 
of MI in the heterozygous genotype of the Arg16Gly variation.
BMI, body mass index; CHD, coronary heart disease; MI, myocardial infarction.BMC Medicine 2007, 5:1 http://www.biomedcentral.com/1741-7015/5/1
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strongly concordant, generating the haplotypes -47Cys/
27Glu (83.5% of -47Cys homozygotes are 27Glu
homozygotes). The five most common haplotypes
accounted for 73.2% of all observed haplotypes.
Use of antihypertensive or lipid-lowering medication was
distributed equally in the genotype subgroups and con-
sisted of angiotensin-converting enzyme inhibitors (n =
128; 29.8%), β-receptor blockers (n = 87; 20.3%), diuret-
ics (n = 70; 16.3%), calcium-channel blockers (n = 86;
20.0%), nitrates (n = 41; 9.6%) and α-receptor blockers (n
= 1; 0.2%). Of the 40 patients on lipid-lowering medica-
tion, 37 were using statins and 3 fibrates. Total cholesterol
and triglycerides measurement was available for 360
patients, and lipoprotein determination for 278 patients.
The mean ± SD AHI in our study group was 29.1 ± 23.1
events per hour, and the mean minimal nocturnal oxygen
saturation was 81.0 ± 10.9%. Linear and independent
relationships between the AHI and daytime systolic and
diastolic BP, daytime heart rate, the prevalence of hyper-
tension, and HDL-C serum levels have been shown in this
study group previously [4]. Because DNA tests could not
be performed for all members of the parent study cohort
(n = 540), we performed a new, adjusted regression for
our subgroup of 429 subjects [7]. Multivariate linear or
logistic regressions revealed a significant influence of the
severity of OSA on daytime systolic BP (β = 0.129, P =
0.008), diastolic BP (0.129, P = 0.012), heart rate (β =
0.197. P < 0.001) prevalence of hypertension (β = 0.026,
P = < 0.001), and HDL-C serum levels (n = 78, β = -0.146,
P = 0.003)[7]. This influence was independent of diabetes,
BMI, age, sex, or antidiabetic, lipid-lowering, or antihy-
pertensive treatments.
As shown in Table 2, the β2-adrenergic receptor polymor-
phisms did not modulate these relationships (Table 2;
hypertension is shown in Table 1).
There were no significant differences between the β2-
adrenergic receptor genotypes in relation to BMI, AHI
(not shown), medication (not shown) or the prevalence
of hypertension, diabetes, dyslipidemia, and CHD.
Patients heterozygous for the Gln27Glu polymorphism
were significantly older than those with homozygous gen-
otypes (Table 1).
Of the 429 patients with OSA, 27 (6.3%) had survived a
MI. Patients heterozygous for the Arg-47Cys and
Gln27Glu polymorphisms showed a lower rate of sur-
vived MI than those with the homozygous forms. There
was a trend towards a lower rate of survived MI in patients
heterozygous for the Arg16Gly polymorphism (Table 1).
Table 3 shows the cardiovascular risk factors and diseases
for the five most frequent haplotypes. Except for survived
MI, there were no significant differences between the hap-
lotypes. Haplotype 1 with heterozygosity for all three pol-
ymorphisms showed a lower rate of survived MI. As
shown in Table 4, patients heterozygous for all three pol-
ymorphisms had a significantly lower relative risk (RR)
for MI compared with homozygous subjects. Carriers of
the most frequent haplotype 1 (n = 113), with heterozy-
gosity for all three polymorphisms, showed a five-fold
lower prevalence of survived MI (OR = 0.21, P = 0.023).
When the homozygous and heterozygous states of each
polymorphism were pooled into groups, the multivariate
logistic regression model revealed an protective influence
on survived MI, independent of age, BMI, AHI, diabetes,















All 429 130.5 ± 15.7 79.6 ± 9.2 76.8 ± 9.5 360 224.7 ± 39.4 171.5 ± 95.7 278 46.8 ± 14.3 146.6 ± 35.9
Codon -47
Cys/Cys 131 130 ± 1 ± 16.3 79.8 ± 9.4 77.0 ± 9.1 112 226.0 ± 40.3 168.6 ± 76.5 93 46.0 ± 14.3 148.9 ± 32.9
Cys/Arg 195 130.9 ± 15.6 79.6 ± 9.3 76.6 ± 8.9 163 222.5 ± 38.5 175.3 ± 102.5 123 47.3 ± 13.9 144.0 ± 38.6
Arg/Arg 103 130.1 ± 15.1 79.4 ± 8.7 76.9 ± 11.0 85 227.6 ± 40.1 167.9 ± 105.2 62 46.9 ± 15.5 148.3 ± 35.1
P 0.878 0.942 0.924 0.594 0.789 0.796 0.578
Codon 16
Arg/Arg 59 133.6 ± 17.2 80.9 ± 9.3 78.4 ± 9.3 53 228.2 ± 45.7 178.5 ± 114.2 39 49.7 ± 15.9 149.5 ± 34.8
Arg/Gly 197 130.0 ± 15.9 79.8 ± 9.5 76.6 ± 9.4 158 221.4 ± 38.6 164.7 ± 92.5 123 47.0 ± 14.4 143 ± 37.2
Gly/Gly 173 129.9 ± 14.9 79.0 ± 8.9 76.5 ± 9.7 149 227.2 ± 37.8 176.0 ± 91.8 116 45.7 ± 13.8 149.4 ± 34.9
P 0.268 0.389 0.371 0.345 0.496 0.305 0.348
Codon 27
Gln/Gln 109 130.7 ± 14.5 80.2 ± 9.0 77.2 ± 9.2 93 222.7 ± 42.3 175.9 ± 89.4 74 44.9 ± 14.0 145.6 ± 32.9
Gln/Glu 202 130.8 ± 15.2 79.2 ± 9.1 76.6 ± 9.2 164 225.3 ± 38.3 174.1 ± 100.9 128 47.2 ± 14.3 146.5 ± 38.2
Glu/Glu 118 130.5 ± 15.7 79.9 ± 9.5 76.8 ± 10.2 103 224.8 ± 39.4 163.3 ± 93.0 76 48.0 ± 14.8 147.8 ± 35.2
P 0.840 0.592 0.859 0.841 0.585 0.395 0.930
Comparison of blood pressure, heart rate, lipid and lipoprotein values between the different genotypes of the β2-adrenergic receptor 
polymorphisms in untreated patients with OSA. Total cholesterol and triglyceride levels were available for 360 patients and lipid electrophoresis for 
278 patients. There were no significant differences between the genotypes.
SBP, systolic blood pressure; DBP, diastolic blood pressure; HDL, high-density lipoprotein; HR, heart rate; LDL, low-density lipoprotein.BMC Medicine 2007, 5:1 http://www.biomedcentral.com/1741-7015/5/1
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dyslipidemia, hypertension and sex [Arg-47Cys: β = -1.23,
P = 0.032; Arg16Gly: β = -0.94, P = 0.53; Gln27Glu: β = -
1.12, P = 0.27; haplotype 1 (all heterozygous): β = -1.555,
P = 0.04].
Discussion
We analysed β2-adrenergic receptor polymorphisms in a
study group of untreated patients with OSA in whom a
linear and independent relationship between the fre-
quency of nocturnal apnea/hypopnea and daytime systo-
lic and diastolic BP, daytime heart rate, prevalence of
arterial hypertension, and HDL serum levels were shown
previously [4,7]. The elevated sympathetic nerve activity
in patients with OSA [1-3] is suggested to mediate these
effects, especially in relation to the cardiovascular system.
The underlying mechanisms between the severity of OSA
and modulation of lipid serum level have been discussed
in detail elsewhere [7]. The fact that we could not find any
influence despite the sympathetic pathway supports the
notion that the effect of these polymorphisms in vivo is
minor, and confirms previous negative results [15]. Kim et
al investigated 195 Korean subjects and found no differ-
ence between β2-adrenergic receptor genotypes
(Arg16Gly and Gln27Glu) in relation to plasma glucose,
fasting serum insulin, LDL, HDL, or triglyceride levels.
However, in another study of 19 healthy individuals with
propanolol-induced dyslipidemia, a significantly
decreased HDL serum level was found in subjects
homozyous for Gln27 homozygotes, and raised triglycer-
ide levels in subjects homozygous for Glu27 [16].
The genetic role of the β2-adrenergic receptor gene in the
development of hypertension has been the subject of
many population-based studies. The distal segment of
chromosome 5 (5q31.1-qtr), which harbors the β2-adren-
ergic receptor gene, has been linked both to systolic and
to post-exercise diastolic BP in genome-wide scans per-
formed in large study populations [17,18]. In a large sam-
ple of 638 individuals from 212 Polish pedigrees,
maximum linkage to essential hypertension and adjusted
systolic and diastolic BP was found for a marker in close
proximity to the β2-adrenergic receptor gene. However,
no significant association of the Arg16Gly and Gln27Glu
polymorphisms was detected with these parameters in the
same study [19].
The published studies that have shown an influence of
these polymorphisms on BP and hypertension are confus-
ing. On the one hand, the Gly16 and Glu27 genotypes
were significantly associated with the prevalence of hyper-
tension and systolic BP in two large populations of Chi-
nese individuals [20,21]. On the other hand, a more than
twofold increased relative risk for hypertension and
higher BP was detected in homozygous Arg16 carriers
with diabetes [22]. One could argue that this represents a
linkage phenomenon in two different populations, but in
view of the functional relevance of these polymorphisms,
such contradictory results remain difficult to explain.
Finally, in the most extensive and prospective population
based study, the Cardiovascular Health Study, with over
5000 participants, no effect of the Arg16Gly and
Gln27Glu polymorphisms on BP control, new-onset
hypertension, ankle-arm index, carotide intima-media
thickness, or brachial flow-mediated dilation was
Table 3: Risk factors, coronary heart disease and myocardial infarction in haplotypes of the β2-adrenergic receptor.
All
Haplotype 1 Haplotype 2 Haplotype 3 Haplotype 4 Haplotype 5
n (%) 429 113 (26.3) 78 (18.2) 47 (11.0) 42 (9.8) 34 (7.9)
Diabetes, n (% of Hap.) 74 (17.2) 21 (18.6) 12 (15.4) 7 (14.9) 10 (23.8) 5 (14.7)
Hypertension,, n (% of pt) 258 (60.1) 70 (61.9) 48 (61.5) 25 (53.2) 24 (57.1) 21 (61.8)
Dyslipidemia n (% of Hap.) 211 (49.2) 49 (43.4) 38 (48.7) 21 (44.7) 22 (52.4) 16 (47.1)
CHD, n (% of Hap.) 55 (12.8) 14 (12.4) 9 (11.5) 7 (14.9) 3 (7.1) 4 (11.8)
MI, n (% of Hap.) 27 (6.3) 2 (1.8) 6 (7.7) 3 (6.4) 3 (7.1) 4 (11.8)
P = 0.021
• Haplotype 1: T/C at position -47, A/G at position 16, C/G at position 27.
• haplotype 2: C/C at position -47, G/G at position 16, G/G at position 27.
• haplotype 3: T/C at position -47, G/G at position 16, C/G at position 27.
• haplotype 4: T/T at position -47, A/G at position 16, C/C at position 27.
• haplotype 5: T/T at position -47, A/A at position 16, C/C at position 27.
Distribution of cardiovascular risk factors, CHD and MI in the five most frequent statistical haplotypes of the three β2-adrenergic receptor 
polymorphisms. Comparisons between the haplotypes were performed with the χ2 test. Haplotype 1, with heterozygosity in all three 
polymorphisms, showed a significant (P = 0.021) lower rate of MI [n = 113, MI = 2 (1.8%]) compared with the rest of the study group [n = 316, MI 
= 25 (7.9%)]. This corresponds to an odds ratio of 0.21. There were no additional significant relations between clinical diagnoses and the β2-
adrenergic receptor haplotypes. Furthermore, no significant differences in blood pressure, heart rate or lipid levels, respectively, existed between 
the different haplotypes (results not shown). Significant P factor is shown in bold.
CHD, coronary heart disease; Hap., haplotype; MI, myocardial infarction.BMC Medicine 2007, 5:1 http://www.biomedcentral.com/1741-7015/5/1
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detected [23]. Interestingly, in this study cohort, Glu27
carriers (heterozygous and homozygous) had a signifi-
cantly lower risk for coronary events, and there was a sim-
ilar trend for Gly16 carriers [24]. Recently, in the same
study population, it was shown that Glu27 carriers also
have a significantly lower risk for sudden cardiac death
[25].
In contrast to the aforementioned studies, we investigated
a cohort of patients in which an OSA-induced, elevated
sympathetic activity exacerbated BP, heart rate, and HDL
levels. Thus, the known functional relevance of these pol-
ymorphisms in vitro would be likely to be detected in vivo
in such patients. The fact that we could not detect any sig-
nificant result underlines the minor effect of β2-adrener-
gic receptor polymorphisms in the development of these
cardiovascular risk factors, and supports the results of the
Cardiovascular Health Study.
Sympathetic activation also influences the risk of MI [26].
Thus, patients with OSA show a higher incidence of fatal
and non-fatal cardiovascular events [9]. In our study
group, with a mean age of 56 years, we found a high per-
centage of CHD (12.8%) and survived MI (6.3%).
Although no effect was seen on the prevalence of CHD, we
found a clear and independent protective effect of the het-
erozygous β2-adrenergic receptor genotypes on survived
MI. This result again supports the hypothesis that was
deducted form the Cardiovascular Health Study; namely,
that variations of the β2-adrenergic receptor gene influ-
ence vulnerability to coronary events.
In the statistical model that was chosen in the Cardiovas-
cular Health Study, carriers of the Gly variation were
pooled into one group. It is not apparent whether hetero-
zygosity alone is protective, but a protective effect of het-
erozygosity in the β2-adrenergic receptor has already been
shown in pulmonary research. Joos et al examined 587
smokers from the Lung Health Study. Those subjects who
were heterozygous at position 27 of the β2-adrenergic
receptor gene had a significantly lower decline in lung
function at 1-year follow-up compared with the
homozygous genotypes (P < 0.001) [27]. Our results sup-
port those findings; by pooling homozygous and hetero-
zygous individuals into two different groups, we could
show a protective effect of heterozygosity on MI, inde-
pendent of other risk factors such as diabetes, arterial
hypertension, dyslipidemia and BMI in a logistic regres-
sion model. Interestingly, patients heterozygous at posi-
tion 27 were slightly but significantly older in spite of the
lower rate of MI (Table 1). This may be an additional indi-
cator for the protective effect of this polymorphism.
As discussed previously by Loos et al, [27] a reason for the
protective effect of heterozygosity may be a phenomenon
called heterozygous advantage. For example, a study on
the role of the secretor blood group in psoriasis showed
that heterozygosity had a strong protective effect (odds
ratio = 0.17), even though the allele frequencies did not
differ between patients and controls [28]. A possible
mechanism for heterozygote advantage is interaction
between the wild-type and mutant protein isoforms in
heterozygous cells. This is a plausible mechanism for
receptor molecules, especially in cases where they form
dimers. Heterodimeric receptors consisting of a wild-type
and a mutant protein isoform may have different agonist-
binding, signal-transduction or agonist-promoted desen-
sitation properties than wild-type or mutant homodim-
ers. Several lines of evidence indicate that β2-adrenergic
receptors form dimers like other G-protein-coupled recep-
tors. The formation of β2-adrenergic receptor dimers was
shown to have functional effects on receptor-stimulated
adenylate cyclase activity [29]. Furthermore, the results of
a study of a mutant β2-adrenergic receptor (Cys341Gly)
suggested that the dimer is the active form of the receptor
[30].
Limitations of the study
Lipid and lipoprotein serum levels were not available for
all patients. Therefore, the diagnosis of dyslipidemia had
to be determined by anamnesis alone in some cases,
which may have led to inaccuracies in the multivariate
regression. The diagnosis of CHD was determined by
anamnesis and was not controlled by coronary arteriogra-
phy. Thus, our proportion of 12.8% may not reflect the
real incidence of CHD.
Table 4: Relative risk for myocardial infarction in OSA patients heterozygous for β2-adrenergic receptor polymorphisms.
n (%) Relative risk for myocardial infarction: odds ratio (95% confidence interval) P
All 429
Heterozygote: Cys-47Arg 195 (45.2) 0.32 (0.13–0.82) 0.012
Heterozygote: Arg16Gly 197 (45.9) 0.39 (0.16–0.94) 0.031
Heterozygote: Gln27Glu 202 (47.1) 0.37 (0.15–0.89) 0.023
Haplotype Cys-47Arg/Arg16Gly/Gln27Glu 113 (26.3) 0.21 (0.05–0.90) 0.023
Significant P factors are shown in bold.BMC Medicine 2007, 5:1 http://www.biomedcentral.com/1741-7015/5/1
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Because our hypothesis included several risk factors for
CHD and MI, Bonferroni correction after the statistical
analysis should be discussed. After this correction, the
results for MI would become insignificant. Because of the
explorative character of our study, we refrained from per-
forming Bonferroni corrections here.
Conclusion
We conclude that the investigated β2-adrenergic receptor
polymorphisms do not modulate cardiovascular risk fac-
tors in patients with OSA-induced elevated sympathetic
activity. However, heterozygosity of these polymorphisms
may be protective in reducing the vulnerability to survived
MI, especially if heterozygosity is present for all polymor-
phisms. Because the statistical haplotype with heterozy-
gosity in all three polymorphisms was not included in
previous studies, we believe that this potentially protec-
tive genetic combination should be focussed on in future.
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